Skip to main content

BioXcel Therapeutics, Inc.

BTAIQ
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001720893

No open-market purchases or sales by BioXcel Therapeutics, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $8.69M in total; Oaktree Capital is the only superinvestor holding it.

Members of Congress who traded BTAIQ

No member of Congress has reported a trade in BioXcel Therapeutics, Inc. since 2020.

Source: U.S. House Clerk and Senate Office of Public Records (eFD). Amounts are the ranges filers report.